Lantern Pharma Inc.
LTRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001763950
No open-market purchases or sales by Lantern Pharma Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $12.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 39
- 13F valueReported value at the end of Q2 2026
- $12.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LTRN, Q2 2026
No superinvestor reported holding LTRN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lantern Pharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 (view filing) | May 12 | 2 days | Schalop Lee TroyDirector | PPurchaseCommon stock, $0.001 par value | +48.5K | $2.06 | +$100.0K | New position48.5K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Schalop Lee TroyDirector | PPurchase | −48.5K | $0.00 | $0 | –48.5K after | Derivative |
| May 14, 2026 (view filing) | May 12 | 2 days | Keyser D JeffreyDirector | PPurchaseCommon stock, $0.001 par value | +48.5K | $2.06 | +$100.0K | +106.1%94.3K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Keyser D JeffreyDirector | PPurchase | −48.5K | $0.00 | $0 | –48.5K after | Derivative |
| Jun 13, 2025 (view filing)7:57 PM ET | Jun 13 | Same day | BIOS Fund I, LP and 9 others10% Owner | SSale | −40.0K | $3.09 | −$123.6K | −25.9%114.3K after | 5 lotsDuplicate filing |
| Jun 13, 2025 (view filing)7:50 PM ET | Jun 13 | Same day | Cavu Management, LP and 3 others10% Owner | SSale | −40.0K | $3.09 | −$123.6K | −25.9%114.3K after | 5 lots |
| Jun 13, 2025 (view filing)6:06 AM ET | Jun 10-12 | 3 daysLate | BIOS Fund I, LP and 9 others10% Owner | SSale | −61.6K | $3.38 | −$208.3K | −34.2%118.6K after | 15 lotsDuplicate filing |
| Jun 13, 2025 (view filing)6:01 AM ET | Jun 10-12 | 3 daysLate | Cavu Management, LP and 3 others10% Owner | SSale | −61.6K | $3.38 | −$208.3K | −34.2%118.6K after | 15 lots |
| May 29, 2025 (view filing)9:55 PM ET | May 27-29 | 2 days | BIOS Fund I, LP and 9 others10% Owner | SSale | −56.2K | $2.99 | −$168.4K | −31.0%125.3K after | 15 lotsDuplicate filing |
| May 29, 2025 (view filing)9:53 PM ET | May 27-29 | 2 days | Cavu Management, LP and 3 others10% Owner | SSale | −56.2K | $2.99 | −$168.4K | −31.0%125.3K after | 15 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lantern Pharma Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 842,669 | $3.51M | 4.06% | +842,669 | New |
| CM Management, LLC | 500,000 | $2.08M | 1.32% | +250,000+100.0% | Added |
| Vanguard Capital Management LLC | 425,118 | $1.77M | 0.00% | +93,039+28.0% | Added |
| Renaissance Technologies LLC | 291,039 | $1.21M | 0.00% | +175,039+150.9% | Added |
| BIOS Capital Management, LP | 249,397 | $1.04M | 2.50% | −615,038−71.1% | Reduced |
| Geode Capital Management, LLC | 102,819 | $428.9K | 0.00% | −8,827−7.9% | Reduced |
| Vanguard Fiduciary Trust Co | 49,950 | $208.3K | 0.00% | +343+0.7% | Added |
| Citadel Advisors LLC | 47,895 | $199.7K | 0.00% | +47,895 | New |
| Westside Investment Management, Inc. | 47,850 | $199.5K | 0.03% | −2,200−4.4% | Reduced |
| Quadrature Capital Ltd | 39,593 | $165.1K | 0.00% | +39,593 | New |